Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1^st Annual Mental Health Conference. The conference is being held at the Lotte New York Palace Hotel and virtually from June 27?28, 2022.

The presentation will be available to view on-demand beginning at 7:00 AM ET on Monday, June 27, 2022 through the H.C. Wainwright conference portal and on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com. A webcast recording will be archived on Aptinyx's website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate?rather than block or over-activate?NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.